Group 1 - The first prescription of the innovative drug Seladelpar for the treatment of primary biliary cholangitis was issued in mainland China, marking a significant step in the rare disease treatment field [1] - Approximately 30% to 40% of patients with primary biliary cholangitis do not respond well to current first-line treatments, highlighting the need for more effective innovative therapies [1] - Seladelpar has shown promising results in international clinical studies, effectively improving biochemical indicators in patients and alleviating moderate to severe itching, with good safety profiles [1] Group 2 - The rapid approval of Seladelpar was facilitated by the temporary import policy for urgently needed drugs in Beijing and efficient collaboration with a medical supplies trading company [2] - By September 2025, 48 boxes of Seladelpar were stocked in a bonded area, achieving a "medicine waiting for patients" status, and the drug was delivered to medical institutions within 1.5 hours after customs clearance on January 5, 2026 [2] - The company plans to focus on the medication needs of rare disease patients, leveraging policy advantages in Beijing to enhance international supply chain capabilities and accelerate the introduction of global innovative drugs [2]

Core Viewpoint - The China International Import Expo (CIIE) is significantly accelerating the speed at which innovative drugs enter the Chinese market, transforming the landscape for multinational pharmaceutical companies and benefiting countless patients [3][8]. Group 1: Innovative Drug Launches - A groundbreaking drug for delaying the progression of type 1 diabetes, Trelagliptin, made its Asian debut at the CIIE and received approval for market entry in September [10]. - Sanofi's innovative cardiovascular drugs and Gilead Sciences' long-acting HIV prevention drug, Lenacapavir, were showcased at the CIIE, indicating a trend of faster access to top-tier medications for Chinese patients [6][18]. - The "CIIE speed" is exemplified by Sanofi's drug Dupixent, which received approval in China ahead of the U.S. FDA, showcasing a record time for innovative drugs to benefit Chinese patients [11]. Group 2: Market Strategy and Investment - Multinational pharmaceutical companies are shifting from merely introducing products to deeper, full-industry chain strategies in China, with Sanofi establishing China as an independent strategic market unit [20][22]. - Novartis has conducted over 100 clinical trials in China and aims for 90% of new drug registrations to align with global timelines within the next two years [28]. - Gilead Sciences is focusing on synchronizing its research and development projects in China with global efforts, emphasizing the importance of the Chinese market [23][26]. Group 3: CIIE's Spillover Effect - The CIIE is not only expediting drug launches but also creating a "spillover effect" that enhances the overall healthcare landscape in China, allowing for broader access to innovative treatments [15][17]. - Since its inception, Novartis has had over 40 innovative drugs and indications approved in China, accounting for 40% of its total approvals in the country since 1987 [15]. - The CIIE serves as a high-level open platform that fosters consensus, innovation, and collaboration among pharmaceutical companies, ultimately changing the lives of Chinese patients [17].